RT Journal Article
SR Electronic
T1 Eruptive Melanocytic Nevi Secondary to Encorafenib for BRAF Mutant Metastatic Colorectal Cancer
JF In Vivo
JO In Vivo
FD International Institute of Anticancer Research
SP 441
OP 445
DO 10.21873/invivo.11793
VO 34
IS 1
A1 ALBERTO MENEGUZZO
A1 ANNALISA LAZZAROTTO
A1 MAURO ALAIBAC
YR 2020
UL http://iv.iiarjournals.org/content/34/1/441.abstract
AB A 59-year-old woman, undergoing treatment with encorafenib for metastatic BRAF mutated colorectal cancer, developed during the first two months of therapy multiple eruptive nevi and changes in pre-existing nevi. Development of eruptive nevi has increasingly been reported in association with medications, most frequently conventional immunosuppressants and biologics. Some drugs are associated with eruptive nevi through an indirect effect of their mechanism of action, whereas other drugs are directly implicated in melanocyte proliferation. In this regard, BRAF inhibitors have been demonstrated to activate the MAPK pathway, and to promote cellular proliferation and survival, therefore leading to the development of new melanocytic nevi and to an increase in the size and hyperpigmentation of pre-existing nevi. A dermatological assessment and follow-up should be recommended in all patients presenting with eruptive nevi, regardless of the pathogenesis, because a high number of acquired melanocytic nevi may represent an adjunctive risk factor for melanoma.